These analyses revealed that SGLT-2i treatment substantially reduces not only macrophage infiltration but also the suppression of inflammatory M1 markers, including tumor necrosis factor-alpha, interlukerin-1 (IL-1), and IL-6, which play a significant role in the improvement of atherosclerosis. This evidence concerns the gene IL6 and atherosclerosis.